Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
Hardik Goswami, Adnan Alsumali, Yiling Jiang, et al.
PharmacoEconomics (2022) Vol. 40, Iss. 7, pp. 699-714
Open Access | Times Cited: 29

Showing 1-25 of 29 citing articles:

Drug treatment of COVID-19 infection
Grace Lui, Giovanni Guaraldi
Current Opinion in Pulmonary Medicine (2023) Vol. 29, Iss. 3, pp. 174-183
Open Access | Times Cited: 30
A longitudinal description of the health-related quality of life among high-risk individuals after SARS-CoV-2 infection: a Dutch multicenter observational cohort study
Magda Vergouwe, Emma Birnie, Sarah van Veelen, et al.
Open Forum Infectious Diseases (2025) Vol. 12, Iss. 2
Open Access | Times Cited: 1
Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial
May Ee Png, Victoria Harris, Jenna Grabey, et al.
British Journal of General Practice (2024) Vol. 74, Iss. 745, pp. e570-e579
Open Access | Times Cited: 7
Cost-effectiveness of nirmatrelvir/ritonavir for high-risk adult outpatients with COVID-19 in Japan
Takahito Mizuno, Yu Kondo, Mikiyasu Sakai, et al.
Journal of Infection and Chemotherapy (2024) Vol. 30, Iss. 8, pp. 716-724
Closed Access | Times Cited: 6
Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial
Sady Alpizar, José Accini, Duane C. Anderson, et al.
Journal of Infection (2023) Vol. 87, Iss. 5, pp. 392-402
Open Access | Times Cited: 13
Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States
Josh J. Carlson, V. Foos, Adam Kasle, et al.
Value in Health (2023) Vol. 27, Iss. 2, pp. 164-172
Open Access | Times Cited: 12
Real-world cost-effectiveness of nirmatrelvir-ritonavir as treatment for SARS-CoV-2 infection in the Belgian setting with omicron variant
Sophie Marbaix, Steven Simoens, Philippe Clevenbergh, et al.
Frontiers in Public Health (2025) Vol. 12
Open Access
Cost-effectiveness of nirmatrelvir/ritonavir in COVID-19 patient groups at high risk for progression to severe COVID-19 in the Netherlands
Carlos Duarte, Michel L. Peters, Michelle H. M. de Goeij, et al.
Cost Effectiveness and Resource Allocation (2025) Vol. 23, Iss. 1
Open Access
Cost‐Effectiveness of Nirmatrelvir/Ritonavir in COVID‐19 Patients at High‐Risk for Progression in Spain
José Ramón Azanza Perea, Juan González del Castillo, R Germán Ferrando, et al.
Journal of Medical Virology (2025) Vol. 97, Iss. 3
Open Access
Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in High-Risk Older Adults in Japan
Hardik Goswami, Atsushi Tajima, Taizo Matsuki, et al.
PharmacoEconomics - Open (2025)
Open Access
A sensitive UPLC-MS/MS method for the simultaneous assay and trace level genotoxic impurities quantification of SARS-CoV-2 inhibitor-Molnupiravir in its pure and formulation dosage forms using fractional factorial design
Srinivas Nakka, Siva Krishna Muchakayala, Surendra Babu Manabolu Surya
Results in Chemistry (2023) Vol. 6, pp. 101019-101019
Open Access | Times Cited: 9
Admission screening testing of patients and staff N95 respirators are cost-effective in reducing COVID-19 hospital-acquired infections
Fenella McAndrew, Romesh Abeysuriya, Rachel Sacks‐Davis, et al.
Journal of Hospital Infection (2024) Vol. 152, pp. 81-92
Closed Access | Times Cited: 2
Therapeutic potential of compounds targeting SARS-CoV-2 helicase
Matthew Halma, Mark Jacobus Anthonius Wever, Sanne Abeln, et al.
Frontiers in Chemistry (2022) Vol. 10
Open Access | Times Cited: 9
Admission Screening Testing of Patients and Staff N95 Masks are Cost-Effective in Reducing COVID-19 Hospital Acquired Infections
Fenella McAndrew, Romesh Abeysuriya, Rachel Sacks‐Davis, et al.
(2024)
Closed Access | Times Cited: 1
A cost-effectiveness analysis of South Africa’s COVID-19 vaccination programme
Ijeoma Edoka, Sheetal Silal, Lise Jamieson, et al.
Vaccine (2024) Vol. 42, Iss. 20, pp. 125988-125988
Open Access | Times Cited: 1
Early Treatment with Fluvoxamine among Patients with COVID-19: A Cost-Consequence Model
Fergal P. Mills, Gilmar Reis, Lindsay A. Wilson, et al.
American Journal of Tropical Medicine and Hygiene (2022) Vol. 108, Iss. 1, pp. 101-106
Open Access | Times Cited: 5
A cost-effectiveness analysis of Molnupiravir and Paxlovid in three African countries
Ijeoma Edoka, Tom Drake, Peter Baker, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Budget impact of oral nirmatrelvir/ritonavir in adults at high risk for progression to severe COVID-19 in the United States
Rickard Sandin, David L. Veenstra, Mathilde Vankelegom, et al.
Journal of Managed Care & Specialty Pharmacy (2023) Vol. 29, Iss. 12, pp. 1290-1302
Open Access | Times Cited: 2
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review
C Veijer, Marinus van Hulst, Benjamin Friedrichson, et al.
PharmacoEconomics (2024) Vol. 42, Iss. 6, pp. 633-647
Open Access
Prevention is better than healing. Clinical and economic implications of oral antiviral agents in COVID-19: a prospective study
Filomena Pietrantonio, Francesco Rosiello, Matteo Ruggeri, et al.
Italian Journal of Medicine (2024) Vol. 18, Iss. 2
Open Access
Can expected error costs justify testing a hypothesis at multiple alpha levels rather than searching for an elusive optimal alpha?
Janet Aisbett
PLoS ONE (2024) Vol. 19, Iss. 9, pp. e0304675-e0304675
Open Access
Low antiviral uptake of nirmatrelvir/ritonavir and molnupiravir in adult patients with COVID-19 in Taiwan in 2022
Fu‐Der Wang, Phung‐Anh Nguyen, David Lee, et al.
Journal of Global Health (2024) Vol. 14
Open Access
Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach
Matthew Sussman, Jennifer Benner, Tendai Mugwagwa, et al.
Journal of Market Access & Health Policy (2024) Vol. 12, Iss. 4, pp. 326-341
Open Access
Cost-effectiveness of outpatient COVID-19 antiviral treatment with Nirmatrelvir/Ritonavir versus usual care in Swedish patients with various risk factors.
Fredrik Nilsson, Martina Aldvén, Christian Gerdesköld, et al.
Journal of Medical Economics (2024), pp. 1-15
Open Access
Cost-Utility of Monulpiravir in COVID-19 Treatment: An Estimation in Vietnam Situation
Nam Xuan Vo, Ngan Nguyen Hoang Le, Trinh Dang Phuong Chu, et al.
(2023)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top